Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Gastro Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Gastro Other
    Anti-IL-5 Therapy Mepolizumab Effective, Well Tolerated in Paediatric Eosinophilic Oesophagitis: Presented at GASTRO 2009 (UEGW/WCOG) - (DGDispatch)
    Benefits of Infliximab-Azathioprine Sustained at 1 Year in Patients With Crohn's Disease: Presented at GASTRO 2009 (UEGW/WCOG) - (DGDispatch)
    Medical Image Quality on iPhone Sufficient for Doctors to Make Accurate Appendicitis Diagnoses: Presented at RSNA - (DGDispatch)
    Endoscopic Ultrasound-Fine Needle Aspiration Feasible, Safe for Children - (DGNews)
    Endoscopic Ultrasound-Fine Needle Aspiration Predicts 5-year Survival in Pancreatic Endocrine Tumours - (DGNews)

    News archive

     Recent webcasts/CME - Gastro Other
    • Modifying Treatment, Maximizing Benefit: A Case-Based Exploration of Advanced CRC Management
    • Applying Evidence to Improve Outcomes in Mild-to-Moderate Ulcerative Colitis: A Roundtable Discussion
    • Goals of Therapy for Mild-to-Moderate Ulcerative Colitis: What is Achievable?
    • Opioid Induced Constipation in Palliative Care : Consideration in the Care of a Unique Population
      Carcinoid Tumors of the Gastrointestinal Tract

      Webcasts/CME archive

       Recent cases - Gastro Other
        Lipemic Serum In Hyperlipidemic Pancreatitis
        Yellow-White Lesions in the Upper Gastrointestinal Tract
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Pancreatic Injury Successfully Treated with Endoscopic Stenting for Major Pancreatic Duct Disruption
        Jejuno-Jejunal Invagination Caused by Epithelioid Sarcoma: A Case Report

        Cases archive
          




        my personal edition > gastro other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Combination Drug Improves Adherence, Tolerability to NSAID Therapy: Presented at ACG

        By Bruce Sylvester

        SAN DIEGO -- October 28, 2009 -- An experimental combination pill appears to improve patients' adherence to nonsteroidal anti-inflammatory drug (NSAID) therapy among those at-risk of upper gastrointestinal symptoms, researchers said here at the American College of Gastroenterology (ACG) 74th Annual Scientific Meeting.

        "Our data suggests that optimising adherence to gastrointestinal protection therapy may improve NSAID tolerability and may result in sustained use," said Jay Goldstein, MD, University of Illinois, Chicago, Illinois, in an oral presentation on October 27.

        Dr. Goldstein said that treatment of chronic pain, especially for patients with arthritis, often requires long-term therapy with NSAIDs. "Patient adherence to prescribed chronic NSAID therapy can be impacted by poor upper gastrointestinal tolerability," he said.

        Therefore, Dr. Goldstein and colleagues recruited patients to take the combination drug PN400, which consists of fixed-dose immediate-release esomeprazole 20 mg and enteric-coated naproxen 500 mg.

        The researchers analysed efficacy and safety of PN400 in 2 phase 3 clinical studies that compared the combination pill to naproxen alone, determining how patients fared on validated measurements of illness, the Severity of Dyspepsia of Assessment, and the Overall Treatment Evaluation of Dyspepsia.

        In the 2 trial 426 patients were assigned to PN400 and 426 patients were assigned to naproxen alone. Dr. Goldstein said the patients receiving the combination product experienced a significantly greater reduction in Severity of Dyspepsia Assessment pain intensity.

        The decrease from baseline for those on PN400 was: -5.51 points compared with -0.15 points for those on naproxen alone (P < .001) in 1 study and -2.64 points for PN400 versus 0.09 point increase for those taking monotherapy naproxen (P = .004) in the second study.

        In addition, Dr. Goldstein said patients treated with PN400 demonstrated further reductions from baseline for non-pain symptoms and achieved higher satisfaction scores.

        The results on the Overall Treatment Evaluation of Dyspepsia test demonstrated similar efficacy. About 45.6% of patients taking PN400 reported positive changes after 6 months of therapy compared with 27.8% of patients on naproxen in 1 study (P < .001); in the second study, 42.9% of patients taking PN400 reported positive changes compared with 34.4% taking patients on naproxen alone.

        Dr. Goldstein also said that patients taking the combination product reported fewer adverse events in both of the phase 3 studies. He found that 242 of the 391 evaluable patients on PN400 were heartburn-free at 6 months compared with 115 of 367 evaluable patients on naproxen alone (P < .001).

        Funding for this study was provided by POZEN, Inc.

        [Presentation title: PN400 Significantly Improves Upper Gastrointestinal Tolerability Compared With Enteric-Coated Naproxen Alone in Patients Requiring Chronic NSAID Therapy: Results From Two Prospective, Randomized, Controlled Trials. Abstract 25]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send